

**LAG3 Antibody (Center) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP6987c****Specification**

---

**LAG3 Antibody (Center) Blocking Peptide - Product Information**Primary Accession [P18627](#)**LAG3 Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 3902**Other Names**

Lymphocyte activation gene 3 protein, LAG-3, Protein FDC, CD223, LAG3, FDC

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6987c](/products/AP6987c) was selected from the Center region of human LAG3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**LAG3 Antibody (Center) Blocking Peptide - Protein Information****Name** LAG3 ([HGNC:6476](#))**Synonyms** FDC**Function**

Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed: [7805750](http://www.uniprot.org/citations/7805750), PubMed: [8647185](http://www.uniprot.org/citations/8647185), PubMed: [20421648](http://www.uniprot.org/citations/20421648)). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and

CD4(+) T-cells (PubMed:<a href="http://www.uniprot.org/citations/7805750" target="\_blank">7805750</a>, PubMed:<a href="http://www.uniprot.org/citations/8647185" target="\_blank">8647185</a>, PubMed:<a href="http://www.uniprot.org/citations/20421648" target="\_blank">20421648</a>). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:<a href="http://www.uniprot.org/citations/8647185" target="\_blank">8647185</a>).

**Cellular Location**

[Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein

**Tissue Location**

Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.

**LAG3 Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**LAG3 Antibody (Center) Blocking Peptide - Images****LAG3 Antibody (Center) Blocking Peptide - Background**

Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains.

**LAG3 Antibody (Center) Blocking Peptide - References**

Smyth,D.J., et.al., BMC Med. Genet. 7, 20 (2006)